Dyslipidemias: Clinical Trials

417 trials for Dyslipidemias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

338 completed, 22 unknown, 17 recruiting, 16 terminated. 417 Phase 1, 45 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1417Completed 338, Unknown 22, Recruiting 17, Terminated 16, Not yet recruiting 12, Active not recruiting 5, Withdrawn 5, Enrolling by invitation 2
Phase 245Completed 32, Recruiting 4, Terminated 3, Unknown 3, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1

Follow Dyslipidemias: new trials by email Literature Review of Dyslipidemias trials Research Report on Dyslipidemias

Trials (filtered) newest first · largest first

All 417 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 1 / Phase 2Not yet recruitingEditas Medicine, Inc.562026-11-012026-10-26
A Phase 1 Study of VELA-101 in Adult Participants
VELA-101, Placebo - Healthy Participants, Hyperlipidemia
Phase 1Not yet recruitingUrsa Medicines602026-11-012026-10-15
A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers
COR-2003, Placebo, COR-1004 + COR-2003 - Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL
Phase 1Not yet recruitingCorsera Health1082026-10-012026-10-05
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly Elevated LDL-C Levels
HS-10582, Placebo - Dyslipidemia
Phase 1Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.762026-09-302026-08-20
Study of ECC4703 With Sulfasalazine and Pitavastatin
ECC4703, Sulfasalazine, Pitavastatin - Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia
Phase 1RecruitingEccogene402026-08-072026-09-10
Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers
Test Drug, Reference Drug - Hypercholerolemia, Dyslipidemia
Phase 1CompletedAJU Pharm Co., Ltd.612026-08-062026-09-09
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B
Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B) - Hyperlipidemia, Diabete Type 2
Phase 1Not yet recruitingAddpharma Inc.442026-07-292026-07-28
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants
SAL0167 group, SAL0167 placebo group - Hyperlipidemia
Phase 1Not yet recruitingShenzhen Salubris Pharmaceuticals Co., Ltd.1202026-07-212026-07-23
Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants
BMS-986533, Famotidine, Placebo - Healthy Volunteers
Phase 1RecruitingBristol-Myers Squibb1362026-07-132026-07-24
A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers
Investigational Product 1, Investigational Product 2, Investigational Product 1 + Investigational Product 2 - Hypertension, Dyslipidemia
Phase 1RecruitingKorea United Pharm. Inc.362026-07-012026-07-06
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 - Elevated LDL-C and High Cholesterol
Phase 1RecruitingMonash University642026-06-302026-09-21
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205
MWX205, Placebo - Dyslipidemias
Phase 1Not yet recruitingShanghai Minwei Biotechnology Co., Ltd372026-06-222026-06-10
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia
Phase 1CompletedAJU Pharm Co., Ltd.412026-06-112026-07-10
The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers
Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg - Healthy, Fasting
Phase 1CompletedLG Chem282026-06-112026-09-10
A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults
Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP - Healthy Participants
Phase 1CompletedAstraZeneca182026-06-102026-09-28
A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants
HRS-1301 Tablets, Atorvastatin Calcium Tablets, Midazolam oral solution - Hyperlipidemias
Phase 1CompletedShandong Suncadia Medicine Co., Ltd.162026-06-082026-09-30
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C
AD-231, AD-231A, AD-231D and AD-231C - Dyslipidemia, Hypertension
Phase 1Not yet recruitingAddpharma Inc.602026-06-012026-05-15
Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)
BSA204, Placebo - Dyslipidemias
Phase 1Active not recruitingBisirna Therapeutics (Suzhou) Co., Ltd.402026-04-202026-08-19
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults
AZD4954, Laroprovstat - Healthy Participants
Phase 1CompletedAstraZeneca312026-04-102026-08-04
A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults
Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2 - Healthy Participants
Phase 1CompletedAstraZeneca442026-03-162026-06-17

Showing 20 of 417. Sign in to see all of them.

Narrower conditions

Hyperlipidemias (113)  ·  Hypercholesterolemia (105)  ·  Hypertension (63)  ·  Lecithin Cholesterol Acyltransferase Deficiency (50)  ·  Hypertriglyceridemia (38)  ·  Hyperlipoproteinemia Type II (19)  ·  Cardiovascular Diseases (17)  ·  Obesity (13)  ·  Diabetes Mellitus (12)  ·  Diabetes Mellitus, Type 2 (12)  ·  Atherosclerosis (11)  ·  Metabolic Diseases (11)  ·  Fasting (10)  ·  Lipid Metabolism Disorders (8)

Broader conditions

Nutritional and Metabolic Diseases (416)  ·  Lipid Metabolism Disorders (409)  ·  Metabolic Diseases (406)  ·  Hyperlipidemias (133)  ·  Vascular Diseases (81)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (79)  ·  Genetic Diseases, Inborn (77)  ·  Lipid Metabolism, Inborn Errors (77)  ·  Metabolism, Inborn Errors (75)  ·  Cardiovascular Diseases (74)  ·  Hypoalphalipoproteinemias (50)  ·  Hypolipoproteinemias (50)  ·  Glucose Metabolism Disorders (33)  ·  Endocrine System Diseases (25)

Interventions

Rosuvastatin Calcium (29)  ·  Atorvastatin (24)  ·  Ezetimibe (14)  ·  Metformin (10)  ·  alirocumab (10)  ·  CKD-519 (8)  ·  Drug Evaluation (8)  ·  Niacin (8)  ·  Simvastatin (8)  ·  Telmisartan (8)  ·  Amlodipine (6)  ·  bococizumab (6)  ·  Fenofibrate (5)  ·  MK-0524 (5)  ·  TA-8995 (5)

Sponsors

Chong Kun Dang Pharmaceutical (44)  ·  AstraZeneca (24)  ·  Pfizer (19)  ·  Merck Sharp & Dohme LLC (16)  ·  IPCA Laboratories Ltd. (12)  ·  Par Pharmaceutical, Inc. (11)  ·  Sanofi (9)  ·  Eli Lilly and Company (8)  ·  Addpharma Inc. (7)  ·  Dr. Reddy's Laboratories Limited (7)  ·  Novartis Pharmaceuticals (7)  ·  Yuhan Corporation (6)  ·  Boryung Pharmaceutical Co., Ltd (5)  ·  Bristol-Myers Squibb (5)  ·  Jeil Pharmaceutical Co., Ltd. (5)

Countries

United States (126)  ·  South Korea (90)  ·  China (39)  ·  Canada (25)  ·  United Kingdom (25)  ·  Australia (21)  ·  India (18)  ·  New Zealand (9)  ·  Belgium (7)  ·  Germany (7)  ·  Netherlands (6)  ·  Brazil (4)  ·  France (4)  ·  Japan (3)  ·  Moldova (3)

Top investigators

Yook-Hwan Noh, M.D., PhD. (4)  ·  David Han, MD (3)  ·  Ashley Brooks (2)  ·  Dr. Hardik Dave, M.B.B.S. (2)

Results publications

PMID 37994400, PMID 28181260, PMID 40587053, PMID 24782116, PMID 31776293, PMID 38504437, PMID 14605787, PMID 14662594, PMID 15324521, PMID 18068514, PMID 18201934, PMID 19500003, PMID 19833861, PMID 19843338, PMID 20457158, PMID 21120461, PMID 21252253, PMID 21417623, PMID 21593349, PMID 21831304, PMID 21952084, PMID 22008366, PMID 22435370, PMID 22743313, PMID 22775199, PMID 22970753, PMID 23638799, PMID 23706094, PMID 23713767, PMID 24077434, PMID 24094767, PMID 24206527, PMID 25202920, PMID 25256660, PMID 25393536, PMID 25889044, PMID 25942458, PMID 26179237, PMID 26261033, PMID 26510577, PMID 26607938, PMID 26628614, PMID 27184170, PMID 27287699, PMID 27596224, PMID 27959715, PMID 27986651, PMID 28204912, PMID 28271017, PMID 28279967

NIH funding

2015 (5), 2009 (1), 2019 (1), 2025 (1), K23HL091130 (1), M01RR000334 (1), P01HL059407 (1), R01HL108160 (1), R21AG023805 (1), R21NR011281 (1), U01AI068632 (1), U54DK083912 (1), ZIAHD000641-23 (1)